# Superfluid Dx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/superfluid-dx

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.superfluiddx.com
- Total disclosed funding: $8.2M
- Latest round: Series A (Dec 20, 2023)
- Investors on record: 5

## About

Based in California, US, and founded in 2015 by Eric Topol and Stephen Quake, Superfluid Dx, Inc., f.k.a. Molecular Stethoscope, Inc., a.k.a. Superfluid Dx operates as a health tech company that focuses on developing precise and clinically valuable diagnostic tests through advancements in molecular biology, bioinformatics, and drug development. The company harnesses cell-free mRNA (cf-mRNA) to develop diagnostics. In December 2023, Superfluid Dx, Inc. raised a Series A funding led by WRQ Sciences, with participation from the Alzheimer's Drug Discovery Foundation. As of May 2024, the company is led by its CEO, Gajus Worthington.

The company provides a platform technology using cell-free mRNA (cf-mRNA) for early detection and management of neurodegenerative diseases, including Alzheimer's. The platform’s minimally invasive approach eliminates the need for invasive procedures like spinal taps and inaccurate brain scans. Superfluid's technology facilitates ongoing monitoring and guides therapy decisions by repeating assessments of a patient's disease state over time.

Superfluid Dx plans to use its proceeds from December 2024 funding to develop affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias and advance the clinical development of more targeted treatments.

## Funding rounds

- Series A, Dec 20, 2023 — Alzheimer's Drug Discovery Foundation, WRQ Sciences
- Seed, Jan 5, 2017, $8.2M — Index Ventures, Pfizer Inc., DCVC

## Investors

- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Seed
- Pfizer Inc. — Seed
- DCVC (https://capitalatlas.ai/funds/dcvc) — Seed
- Alzheimer's Drug Discovery Foundation — Series A
- WRQ Sciences (https://capitalatlas.ai/funds/wrq-sciences) — Series A